ArisGlobal, a leading life sciences technology provider has announced that China-based Fosun Pharma has selected LifeSphere Safety MultiVigilance (LSMV) as its global pharmacovigilance system. Fosun will utilize ArisGlobal's technology to achieve full E2B (R3) compliance with greater efficiency and compliance. The selection was made in conjunction with ArisGlobal partner Epharma Healthcare Technology Co., Ltd, a one-stop solution provider for the pharmaceutical research and development industry.

Fosun Pharma and Epharma join a growing list of biopharmaceutical companies and health authorities making the decision to replace current pharmacovigilance systems with ArisGlobal's LSMV solution suite. Epharma is an official retail partner for ArisGlobal and will help the company promote the product in the Chinese region. LifeSphere Safety MultiVigilance is currently used by more than 200 life sciences companies, including 9 health authorities.

"Advanced technology, such as artificial intelligence and machine learning, are key LSMV capabilities that help us automate repetitive, manual tasks, thus improving efficiency and compliance," said a spokesperson for Fosun Pharma. "By switching to LifeSphere Safety MultiVigilance, our efforts to comply with regulations will be much more efficient."

"ArisGlobal offers the most innovative safety, clinical, regulatory, and medical affairs solutions in the Chinese market," said Sankesh Abbhi, President and CEO, ArisGlobal. "Fosun Pharma is just one example how our customers in China can efficiently and inexpensively meet a wide range of requirements for regulatory compliance and patient safety."